Just chatting about BlastX wound gel when I thought about two people I know who had real issues with a Flesh-Eating-Bacteria problem here in Melbourne.

Suspect a Doctor or two will be way ahead of me. I thought a thread on wound care, treatment and recovery times might be of interest to many of us.

Australia Has a Flesh-Eating-Bacteria Problem

In the beach towns south of Melbourne, everyone, it seems, knows someone who’s been attacked.

The technical term is "Buruli ulcers" which are caused by the bacterium Mycobacterium ulcerans."

Love to see a study on this. Suspect SurgX and BlastX™ would be of great interest to the issue.

"Buruli ulcer is a chronic debilitating disease that mainly affects the skin and sometimes bones. First described by Sir Albert Cook in 1897 in Uganda, it was not until the 1930s that Australian scientists led by Peter MacCallum first succeeded in culturing the organism from lesions of patients from the Bairnsdale region. The name Buruli comes from an area of Uganda where many cases were reported in the 1960s. In Africa, about half of the patients are children under 15 years. In Australia, the average age is around 60 years. In 1998, WHO established the Global Buruli Ulcer Initiative in response to the growing spread of the disease, particularly in West Africa. Buruli ulcer is caused by Mycobacterium and belongs to the family of bacteria that causes tuberculosis and leprosy. Although the causative organism of Buruli ulcer is an environmental bacterium, the mode of transmission to humans remains unknown. The organism produces a unique toxin – mycolactone – that causes the damage to the skin. Early diagnosis and treatment are crucial to minimizing morbidity, costs and prevent long-term disability. "
Link


Diabetics wound care is already a known Strength for Next Science . The Cost savings ( in my own case months less time for my surgical wound to recover is priceless ) Save money and significantly improve outcomes.
NSX has a little bit of JOB to let everyone get access to these amazing products.
Cost-utility of a biofilm-disrupting gel versus standard of care in chronic wounds: a Markov microsimulation model based on a randomised controlled trial